Jim Simons Entera Bio Ltd. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Entera Bio Ltd. stock. As of the latest transaction made, Renaissance Technologies LLC holds 74,900 shares of ENTX stock, worth $135,569. This represents 0.0% of its overall portfolio holdings.

Number of Shares

74,900

Previous 57,400 30.49%

Holding current value

$135,569

Previous $34,000 267.65%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.64 - $1.72 $11,200 - $30,100	17,500 Added 30.49%	74,900 $125,000
Q4 2023 Feb 13, 2024	BUY	$0.55 - $0.74 $18,700 - $25,160	34,000 Added 145.3%	57,400 $34,000
Q3 2023 Nov 14, 2023	BUY	$0.6 - $0.88 $4,380 - $6,424	7,300 Added 45.34%	23,400 $17,000
Q2 2023 Aug 11, 2023	BUY	$0.68 - $1.01 $3,876 - $5,757	5,700 Added 54.81%	16,100 $14,000
Q1 2023 May 12, 2023	SELL	$0.83 - $1.44 $107,236 - $186,048	-129,200 Reduced 92.55%	10,400 $12,000

Q4 2022 Feb 13, 2023	BUY	$0.5 - $0.73 $59,150 - $86,359	118,300 Added 555.4%	139,600 $102,000
Q3 2022 Nov 14, 2022	BUY	$0.07 - $1.98 $1,491 - $42,174	21,300 New	21,300 $22,000
Q1 2022 May 13, 2022	SELL	$1.91 - $3.23 $76,591 - $129,523	-40,100 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$2.82 - $4.79 $113,082 - $192,079	40,100 New	40,100 $113,000
Q2 2021 Aug 13, 2021	SELL	$2.92 - $6.5 $351,588 - $782,645	-120,407 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$1.16 - $6.9 $55,936 - $332,724	48,221 Added 66.8%	120,407 $459,000
Q4 2020 Feb 10, 2021	BUY	$1.03 - $1.24 $74,351 - $89,510	72,186 New	72,186 $78,000

Others Institutions Holding ENTX

# of Institutions

Shares Held

4.27M

Call Options Held

3.9K

Put Options Held

View Full List

About Entera Bio Ltd.

Ticker ENTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,809,900
Market Cap $52.1M
Description
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed ...

More about ENTX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account